Jupiter Topco LLC Acquires New Position in Ingevity Corporation $NGVT

Key Points

• Jupiter Topco LLC acquired 17,523 shares of Ingevity in the second quarter, valued at approximately $1.31 million. Institutional investors collectively own 91.59% of the company.
• Ingevity exceeded quarterly expectations, reporting adjusted EPS of $1.74 versus the $1.33 consensus estimate and revenue of $314.1 million. The company issued fiscal 2026 EPS guidance of $5.00–$5.45.
• Recent insider activity was negative, with executives selling 17,801 shares worth about $1.35 million over three months. Analysts maintain a consensus “Hold” rating with an average price target of $80, compared with a recent price of $70.56.

Jupiter Topco LLC purchased a new stake in shares of Ingevity Corporation (NYSE:NGVT - Free Report) in the second quarter, according to its most recent filing with the SEC. The firm purchased 17,523 shares of the company's stock, valued at approximately $1,309,000. Jupiter Topco LLC owned 0.05% of Ingevity at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Global Retirement Partners LLC purchased a new position in shares of Ingevity during the 4th quarter worth approximately $27,000. Meeder Asset Management Inc. purchased a new stake in Ingevity in the 4th quarter valued at approximately $33,000. Geneos Wealth Management Inc. lifted its stake in Ingevity by 85.8% in the 2nd quarter. Geneos Wealth Management Inc. now owns 838 shares of the company's stock valued at $36,000 after buying an additional 387 shares in the last quarter. Frazier Financial Advisors LLC purchased a new stake in Ingevity in the 2nd quarter valued at approximately $37,000. Finally, Headlands Technologies LLC acquired a new stake in Ingevity during the 2nd quarter valued at $46,000. Institutional investors and hedge funds own 91.59% of the company's stock.

Ingevity Price Performance

NGVT opened at $70.56 on Friday. Ingevity Corporation has a 1 year low of $45.85 and a 1 year high of $79.29. The company's 50 day simple moving average is $73.06 and its 200 day simple moving average is $71.62. The stock has a market capitalization of $2.43 billion, a PE ratio of 48.00 and a beta of 1.17. The company has a debt-to-equity ratio of 22.52, a quick ratio of 1.15 and a current ratio of 1.61.

Ingevity (NYSE:NGVT - Get Free Report) last issued its quarterly earnings results on Wednesday, July 29th. The company reported $1.74 EPS for the quarter, topping the consensus estimate of $1.33 by $0.41. Ingevity had a net margin of 4.65% and a return on equity of 284.70%. The firm had revenue of $314.10 million during the quarter, compared to analyst estimates of $312.20 million. Ingevity has set its FY 2026 guidance at 5.000-5.450 EPS. As a group, sell-side analysts expect that Ingevity Corporation will post 5.4 EPS for the current year.

Insider Activity

In related news, CEO David H. Li sold 5,000 shares of the company's stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $75.83, for a total transaction of $379,150.00. Following the sale, the chief executive officer directly owned 120,636 shares of the company's stock, valued at approximately $9,147,827.88. This represents a 3.98% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Ryan C. Fisher sold 2,709 shares of Ingevity stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $73.72, for a total transaction of $199,707.48. Following the completion of the transaction, the senior vice president directly owned 15,722 shares of the company's stock, valued at approximately $1,159,025.84. This represents a 14.70% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 17,801 shares of company stock valued at $1,347,481. 0.88% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

NGVT has been the topic of several recent research reports. Wall Street Zen downgraded Ingevity from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 1st. Weiss Ratings upgraded Ingevity from a "sell (d-)" rating to a "hold (c-)" rating in a research report on Friday, July 31st. Two analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $80.00.

Ingevity Company Profile

Ingevity Corporation, traded as NGVT, is a specialty chemicals and performance materials company headquartered in North Charleston, South Carolina. The company operates two primary business units: Performance Chemicals and Performance Materials. The Performance Chemicals segment produces and markets specialty chemicals derived largely from wood and other natural feedstocks, including rosin acids, tall oil fatty acids and esters, as well as specialty petroleum resins. These products serve a broad range of industries, including paper, adhesives, coatings, oilfield drilling and consumer goods.

The Performance Materials segment develops and manufactures activated carbon products and composites for applications such as automotive emissions control, industrial air and water purification, and spill containment.

Want to see what other hedge funds are holding NGVT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ingevity Corporation (NYSE:NGVT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.